Retatrutide is a new treatment in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By stimulating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately contributes to significant weight loss. While studies are